Cyclica collaborates with Enamine to use REAL technology in its ligand design platform for AI-augmented drug design

This article was originally published here

The companies aim to empower Cyclica’s patented, evolutionary algorithm with new design options based on the 73,000 Enamine’s in-stock building blocks and 171 thoroughly validated synthesis procedures. The

The post Cyclica collaborates with Enamine to use REAL technology in its ligand design platform for AI-augmented drug design appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply